Results 211 to 220 of about 58,085 (295)

DIPEPTIDYL PEPTIDASE-4 INHIBITORS: POTENTIAL FOR TREATMENT OF METABOLIC SYNDROME AND DEVELOPED FORMULATION APPROACHES

, 2017
Rakesh Mishra, Shashikant Dhole
openalex   +2 more sources

Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease. [PDF]

Lab Invest
Al Tuhaifi T, Zhong J, Yang HC, Fogo AB.
europepmc   +1 more source

アログリプチンは非糖尿病被験者において食後高脂血症および食後血管内皮機能低下を改善する：予備報告 [PDF]

, 2015
Noda, Yoko
core  

Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. [PDF]

Cureus
Kalra S, Bhattacharya S, Dhingra A, Das S, Kapoor N, Shaikh S, Kolapkar V, Lokesh Kumar RV, Patel K, Kotwal R.   +9 more
europepmc   +1 more source

A case of bullous pemphigoid and renal disease after dipeptidyl peptidase 4 inhibitor administration. [PDF]

CEN Case Rep
Suenaga A, Sawa N, Oba Y, Ikuma D, Sekine A, Yamanouchi M, Hasegawa E, Mizuno H, Suwabe T, Hayashi N, Kono K, Kinowaki K, Ohashi K, Miyazono M, Yamaguchi Y, Ubara Y.   +15 more
europepmc   +1 more source

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study [PDF]

, 2016
HASHIMOTO Naotake, HASUMI Sumiko, HONDA Masashi, IWAMOTO Yasuhiko, KASAHARA Tadasu, NUNOME Hideo, OHASHI Hiroshi, SAKURA Hiroshi, SASAMOTO Kazuo, TOMONAGA Osamu, UJIHARA Noriko   +10 more
core   +2 more sources

Triple Drug Fixed Dose Combination Of Sodium-Glucose Co-transporter 2 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor And Metformin In Type 2 Diabetes In India: A Systematic Review With Meta-Analysis [PDF]

Samit Ghosal, Awadhesh Kumar Singh, Ashok Kumar Das   +2 more
openalex   +1 more source

Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. [PDF]

PLoS One
Harris DD, Sabe SA, Broadwin M, Stone C, Bellam K, Malhotra A, Abid MR, Sellke FW.   +7 more
europepmc   +1 more source

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor. [PDF]

Adv Ther
Evans M, Husain M, Srivastava A, Mangla KK, Kuhlman AB, Lingvay I.   +5 more
europepmc   +1 more source

Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]

Diabetes Obes Metab
europepmc   +1 more source